Business Trends– category –
-
iPSC Parkinson’s Therapy: Japan’s 2026 Regulatory Approval
Testbook India Overview Japan became the first country to grant regulatory approval for an induced Pluripotent Stem Cell (iPSC) therapy for Parkinson's disease in March 2026. The treatment replaces lost neurons via dopaminergic progenito... -
PackGene: Dyno AAV capsid ratio at 10L preclinical scale
PR Newswire China Overview PackGene Biotech announced successful client AAV manufacturing projects via the Dyno Frontiers Network, demonstrating reliable and scalable production across multiple Dyno® capsids. Utilizing its proprietary π-... -
WuXiUP: WuXi Biologics AI bioprocess and 110x productivity
BioProcess International China Overview China's WuXi Biologics has rapidly industrialized biopharmaceutical manufacturing through cell line/process optimization, its WuXiUP continuous bioprocess technology, and AI integration. Notably, t... -
Sartorius Eveo: CAR-T manufacturing costs and 2026 specs
Onyx Newsroom Germany Overview Sartorius introduced its automated Eveo Cell Therapy Platform at the Cell & Gene Meeting on the Mesa, aiming to reduce autologous CAR-T batch costs to under $40,000 per patient and cut capital/operating... -
NK Cell Therapy: Japan’s 2014 RMPA law and expedited approval path
Grand Green Osaka Umekita Clinic Japan Overview Japan's Regenerative Medical Products Act (RMPA), implemented in 2014, facilitates rapid approval for regenerative medicine products, including NK cell therapies, significantly broadening i... -
Perfusion Culture vs Fed-Batch: 2.45x carbon footprint reduction
BioProcess Tools USA Overview BioProcess Tools reports that perfusion bioreactor processes exhibit significantly lower carbon footprints per kilogram of product compared to fed-batch processes. This advantage stems primarily from perfusi... -
miv-cel CAR T-Cell: Kyverna’s 1-year benefit specs for SPS and MG
CGTlive® USA Overview Kyverna Therapeutics reported positive one-year data for mivocabtagene autoleucel (miv-cel), a CD19-directed CAR T-cell therapy, showing durable benefits in patients with Stiff Person Syndrome (SPS) and generalized ... -
AMT-130: uniQure’s 4-year Huntington’s disease progression data
pharmaphorum USA Overview uniQure announced updated four-year results from its Phase 1/2 study of ifezuntirgene inilparvovec (AMT-130) for Huntington's disease, showing a 'meaningful slowing of disease progression' in 12 patients. The ge... -
CRISPR-Cas9: 1-year cholesterol reduction specs for lipid disorder
ScienceDaily (New England Journal of Medicine) USA Overview A Phase 1 clinical trial from Cleveland Clinic reported that a single infusion of a CRISPR-Cas9 gene-editing therapy led to sustained reductions in LDL cholesterol and triglycer... -
CRISPR CD33-Negative Stem Cells: WashU AML therapy explained
WashU Medicine (Nature Medicine) USA Overview Researchers at WashU Medicine successfully used CRISPR to remove CD33 from donor stem cells in a 30-patient trial, demonstrating that these edited cells engrafted and shielded healthy blood c...
